What one share of Verrica Pharmaceuticals holds
We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need.
Verrica Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.84 |
|---|---|
| Profit | −$1.89 |
| Cash and investments | $0.65 |
| Debt | $0.06 |
| Book value | $0.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$15.64 | — | — | — | −$19.03 |
| 2018 | — | −$14.08 | $0.53 | −$12.72 | — | $34.79 |
| 2019 | — | −$11.33 | $0.27 | −$11.28 | — | $25.21 |
| 2020 | — | −$17.08 | $0.59 | −$12.67 | — | $12.97 |
| 2021 | $4.44 | −$12.97 | $0.33 | −$10.53 | — | $11.85 |
| 2022 | $2.64 | −$7.17 | $0.09 | −$5.55 | — | $9.74 |
| 2023 | $1.13 | −$14.78 | $0.08 | −$8.59 | — | $4.66 |
| 2024 | $1.46 | −$14.78 | $0.01 | −$11.77 | — | −$1.07 |
| 2025 | $3.34 | −$1.68 | $0.00 | −$1.65 | — | $1.44 |
Common questions about Verrica Pharmaceuticals
How much does one share of Verrica Pharmaceuticals earn?
Over the last 12 months, Verrica Pharmaceuticals lost $1.89 for each share on $1.84 of sales.
Does Verrica Pharmaceuticals pay a dividend?
Verrica Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Verrica Pharmaceuticals’s book value per share?
Verrica Pharmaceuticals’s book value is $0.25 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Verrica Pharmaceuticals have?
Each share of Verrica Pharmaceuticals has $0.65 of cash and investments and $0.06 of debt, as of June 30, 2026.
Has Verrica Pharmaceuticals bought back shares?
Verrica Pharmaceuticals’s share count rose about 3637% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.